Overview

Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Status:
Active, not recruiting

Trial end date:
2021-12-15

Target enrollment:

Participant gender:

Summary

This is a randomized, open-label and parallel phase I study to compare pharmacokinetics (PK), pharmacodynamics (PD) and safety of goserelin acetate sustained-release microspheres for injection (LY01005) and ZOLADEX® following multiple administration in patients with prostate cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Luye Pharma Group Ltd.

Treatments:

Goserelin